Arcutis Biotherapeutics ARQT
$26.36 −$0.81 (-2.98%)
Market closed · Nov 22, 5:10 am ET · Last extended-hours $26.40 +0.15%
Open$26.91
Prev close$27.17
Day range$26.29 – $27.47
Volume1.29M
Market cap$3.33B
P/E (TTM)119.8
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$143.92M+45.1% YoY
Operating profit$9.44M+10.7% YoY
Net profit$8.80M+18.8% YoY
Diluted EPS$0.06+0.0% YoY
Free cash flow$18.80M+1,171.9% YoY
Operating cash flow$18.90M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin91.2%
Operating margin6.9%
Net margin5.9%
Return on equity14.9%
Return on assets6.7%
Return on invested capital10.8%
Current ratio2.92
Liabilities / assets53.5%
Cash & investments$259.46M
Total debt$114.62M
Net cash (debt)$144.84M
Free cash flow / sales11.7%
Where the revenue comes from
Quarter 2026/Q3
By business line
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $143.92M | $129.86M | $105.40M | $376.07M | $129.50M |
| Total Operating Revenue | $143.92M | $129.86M | $105.40M | $376.07M | $129.50M |
| Cost of Revenue | $12.46M | $10.94M | $9.78M | $36.70M | $11.69M |
| Gross Profit | $131.46M | $118.92M | $95.61M | $339.38M | $117.82M |
| Operating Expense | $122.02M | $102.49M | $104.70M | $351.60M | $99.43M |
| Selling and Admin Expenses | $99.60M | $82.14M | $74.08M | $274.55M | $78.98M |
| Research & Development | $22.42M | $20.36M | $30.63M | $77.05M | $20.45M |
| Operating Profit | $9.44M | $16.43M | -$9.09M | -$12.23M | $18.39M |
| Net Non-Operating Interest Income (Expense) | -$363,000.00 | -$1.13M | -$2.09M | -$3.19M | -$835,000.00 |
| Non-Operating Interest Income | $2.60M | $2.28M | $2.28M | $8.90M | $2.17M |
| Non-Operating Interest Expense | $2.96M | $3.41M | $4.37M | $12.08M | $3.00M |
| Other Income (Expense) | -$77,000.00 | -$157,000.00 | -$20,000.00 | $443,000.00 | $313,000.00 |
| Other Non-Operating Income (Expenses) | -$77,000.00 | -$157,000.00 | -$20,000.00 | $443,000.00 | $313,000.00 |
| Pretax Profit | $9.00M | $15.15M | -$11.20M | -$14.97M | $17.87M |
| Tax | $195,000.00 | $136,000.00 | $93,000.00 | $1.17M | $470,000.00 |
| Net Profit | $8.80M | $15.01M | -$11.30M | -$16.14M | $17.40M |
| Profit from Continuing Operations | $8.80M | $15.01M | -$11.30M | -$16.14M | $17.40M |
| Net Income to Parent Company | $8.80M | $15.01M | -$11.30M | -$16.14M | $17.40M |
| Net Income to Common Stockholders | $8.80M | $15.01M | -$11.30M | -$16.14M | $17.40M |
| Basic EPS | $0.06 | $0.11 | -$0.09 | -$0.13 | $0.14 |
| Diluted EPS | $0.06 | $0.11 | -$0.09 | -$0.13 | $0.13 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $524.43M | $488.54M | $460.00M | $432.97M | $432.97M |
| Total Current Assets | $503.69M | $467.67M | $438.06M | $411.23M | $411.23M |
| Cash and Cash Equivalents & Short-Term Investments | $259.46M | $238.55M | $224.00M | $220.98M | $220.98M |
| -Cash and Cash Equivalents | $33.37M | $34.12M | $34.76M | $42.91M | $42.91M |
| -Short Term Investments | $226.09M | $204.43M | $189.24M | $178.08M | $178.08M |
| Receivables | $171.28M | $155.16M | $144.38M | $146.23M | $146.23M |
| -Accounts Receivable | $171.28M | $155.16M | $144.38M | $146.23M | $146.23M |
| Prepaid Assets | $14.35M | $19.56M | $18.66M | $12.06M | $12.06M |
| Inventory | $45.67M | $38.88M | $37.39M | $22.63M | $22.63M |
| Restricted Cash | $308,000.00 | $308,000.00 | $308,000.00 | $308,000.00 | $308,000.00 |
| Other Current Assets | $12.62M | $15.21M | $13.32M | $9.02M | $9.02M |
| Total Non-Current Assets | $20.74M | $20.87M | $21.95M | $21.74M | $21.74M |
| Net PPE | $4.94M | $5.13M | $5.40M | $5.51M | $5.51M |
| -Gross PPE | $4.94M | $5.13M | $5.40M | $8.76M | $8.76M |
| Goodwill and Other Intangible Assets | $13.13M | $13.69M | $14.25M | $14.81M | $14.81M |
| Other Non-Current Assets | $2.67M | $2.05M | $2.30M | $1.42M | $1.42M |
| Total Liabilities | $280.46M | $267.96M | $270.36M | $243.49M | $243.49M |
| Total Current Liabilities | $172.36M | $160.34M | $163.20M | $129.84M | $129.84M |
| Payables | $8.34M | $6.60M | $18.30M | $12.53M | $12.53M |
| -Accounts Payable | $8.34M | $6.60M | $18.30M | $12.53M | $12.53M |
| Current Accrued Expenses | $135.43M | $131.28M | $126.63M | $95.78M | $95.78M |
| Short-Term Debt and Capital Lease Obligation | $6.95M | $6.95M | $7.95M | $1.00M | $1.00M |
| -Current Debt | $6.95M | $6.95M | $7.95M | $1.00M | $1.00M |
| Total Non-Current Liabilities | $108.10M | $107.62M | $107.15M | $113.66M | $113.66M |
| Long Term Debt and Capital Lease Obligation | $107.67M | $107.19M | $106.72M | $113.23M | $113.23M |
| -Long Term Debt | $102.45M | $101.95M | $101.47M | $107.96M | $107.96M |
| -Long Term Capital Lease Obligation | $5.22M | $5.24M | $5.25M | $5.27M | $5.27M |
| Other Non-Current Liabilities | $431,000.00 | $431,000.00 | $431,000.00 | $431,000.00 | $431,000.00 |
| Total Equity | $243.97M | $220.58M | $189.65M | $189.48M | $189.48M |
| Stockholders' Equity | $243.97M | $220.58M | $189.65M | $189.48M | $189.48M |
| Capital Stock | $12,000.00 | $12,000.00 | $12,000.00 | $12,000.00 | $12,000.00 |
| -Common Stock | $12,000.00 | $12,000.00 | $12,000.00 | $12,000.00 | $12,000.00 |
| Additional Paid-In Capital | $1.37B | $1.36B | $1.34B | $1.33B | $1.33B |
| Retained Earnings | -$1.13B | -$1.13B | -$1.15B | -$1.14B | -$1.14B |
| Gains/Losses Not Affecting Retained Earnings | -$1.17M | -$656,000.00 | -$514,000.00 | -$44,000.00 | -$44,000.00 |
| -Accumulated Depreciation | – | – | – | -$3.25M | -$3.25M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | $18.90M | $12.64M | $2.24M | -$5.63M | $26.19M |
| Net cash flow from continuing operations | $18.90M | $12.64M | $2.24M | -$5.63M | $26.19M |
| Net Income from Continuing Operations | $8.80M | $15.01M | -$11.30M | -$16.14M | $17.40M |
| Depreciation & Depletion & Amortization | $562,000.00 | $563,000.00 | $562,000.00 | $4.67M | $563,000.00 |
| Other Non-Cash Items | $779,000.00 | $757,000.00 | $675,000.00 | $2.41M | $482,000.00 |
| Change in Working Capital | -$3.44M | -$16.23M | $1.79M | -$34.83M | -$2.33M |
| -Change in Receivables | -$16.12M | -$10.79M | $1.85M | -$73.16M | -$31.11M |
| -Change in Inventory | -$6.50M | -$1.18M | -$14.58M | -$7.33M | -$5,000.00 |
| -Change in Prepaid Assets | $7.18M | -$2.55M | -$11.73M | -$2.01M | -$1.27M |
| -Change in Payables and Accrued Expense | $12.01M | -$1.58M | $26.38M | $48.35M | $30.18M |
| -Change in Other Current Liabilities | -$8,000.00 | -$139,000.00 | -$137,000.00 | -$680,000.00 | -$126,000.00 |
| Net cash flow from investing | -$22.08M | -$15.22M | -$11.33M | -$30.25M | -$34.18M |
| Net Cash Flow from Continuing Investing Activities | -$22.08M | -$15.22M | -$11.33M | -$30.25M | -$34.18M |
| Net PPE Purchase and Sale | -$97,000.00 | -$158,000.00 | $0.00 | -$686,000.00 | $0.00 |
| Net Intangibles Purchase and Sale | $0.00 | – | – | -$10.00M | $0.00 |
| Net Investment Purchase and Sale | -$21.99M | -$15.07M | -$11.33M | -$19.57M | -$34.18M |
| Financing Cash Flow | $2.45M | $1.99M | $1.07M | $6.97M | $3.72M |
| Net Cash Flow from Continuing Financing Activities | $2.45M | $1.99M | $1.07M | $6.97M | $3.72M |
| Proceeds from Stock Option Exercised | $2.45M | $2.99M | $1.07M | $6.97M | $3.72M |
| Net Other Financing Charges | $0.00 | – | – | – | – |
| Ending Cash Balance | $33.68M | $34.43M | $35.07M | $43.22M | $43.22M |
| Net Change in Cash | -$733,000.00 | -$595,000.00 | -$8.03M | -$28.91M | -$4.27M |
| Beginning Cash Balance | $34.43M | $35.07M | $43.22M | $71.95M | $47.43M |
| Effect of Exchange Rate Changes | -$15,000.00 | -$46,000.00 | -$119,000.00 | $168,000.00 | $59,000.00 |
| Free Cash Flow | $18.80M | $12.48M | $2.24M | -$16.31M | $26.19M |
| Net Issuance Payments Of Debt | – | – | – | $0.00 | – |
| Net Common Stock Issuance | – | – | – | $0.00 | $0.00 |
No comments yet — be the first to weigh in on ARQT.
Sign in to join the discussion.